ResearcherCross Cancer InstituteActive in the last 2 years
Vickie Elaine Baracos
Matched on ORCID iD 0000-0002-9609-1001; OpenAlex author ID A5010704818, A5104097261. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 6
- Feeding Behaviour in the KPC Model of Pancreatic Cancer-Associated Cachexia: Alteration of Spontaneous and Evoked Feeding Behaviours. Last author DOI 10.1002/jcsm.70262↗
- Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic canc… Co-author DOI 10.1002/ncp.70096↗
- Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanced pancreatic cancer and exocrine pancre… Co-author DOI 10.1016/j.clnu.2024.06.037↗
- Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer. First author DOI 10.3390/cancers15174368↗
- Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Co-author DOI 10.1007/s00330-021-07899-6↗
- The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. First author DOI 10.18632/oncotarget.7773↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vera Christine Mazurak · 3 shared papers, 2023–2026 · strength 0.79
- Paper Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during c… DOI 10.1002/ncp.70096↗
- Paper Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanc… DOI 10.1016/j.clnu.2024.06.037↗
- Paper Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic … DOI 10.3390/cancers15174368↗
- Pamela N. Klassen · 3 shared papers, 2023–2026 · strength 0.79
- Paper Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during c… DOI 10.1002/ncp.70096↗
- Paper Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanc… DOI 10.1016/j.clnu.2024.06.037↗
- Paper Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic … DOI 10.3390/cancers15174368↗
- Michael B. Sawyer · 3 shared papers, 2023–2026 · strength 0.79
- Paper Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during c… DOI 10.1002/ncp.70096↗
- Paper Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanc… DOI 10.1016/j.clnu.2024.06.037↗
- Paper Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic … DOI 10.3390/cancers15174368↗
- Fateema Muzaffar · 1 shared paper, 2026 · strength 0.50
- Christina Kim · 1 shared paper, 2026 · strength 0.33
- Farzad Khalvati · 1 shared paper, 2021 · strength 0.12
- Gerard M. Healy · 1 shared paper, 2021 · strength 0.12
- Masoom A. Haider · 1 shared paper, 2021 · strength 0.12
- Oliver F. Bathe · 1 shared paper, 2021 · strength 0.12
- Emmanuel Salinas-Miranda · 1 shared paper, 2021 · strength 0.12
- Grainne Mary O'Kane · 1 shared paper, 2021 · strength 0.12
- Jennifer Jane Knox · 1 shared paper, 2021 · strength 0.12
- Steve Gallinger · 1 shared paper, 2021 · strength 0.12
- James L. Abbruzzese · 1 shared paper, 2016 · strength 0.07
- Henrique Afonseca Parsons · 1 shared paper, 2016 · strength 0.07
- Eduardo D Bruera · 1 shared paper, 2016 · strength 0.07
- Razelle Kurzrock MD · 1 shared paper, 2016 · strength 0.07
- David S. Hong · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.